 Timothy Jenkins
Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 35 | 2024 | 1510 | 6.500 |
Why?
| | Antimicrobial Stewardship | 11 | 2024 | 95 | 5.240 |
Why?
| | Skin Diseases, Bacterial | 7 | 2016 | 24 | 3.020 |
Why?
| | Otitis Media | 5 | 2023 | 146 | 2.950 |
Why?
| | Inappropriate Prescribing | 6 | 2021 | 51 | 2.120 |
Why?
| | Drug Utilization | 5 | 2020 | 169 | 2.100 |
Why?
| | Practice Patterns, Physicians' | 10 | 2023 | 1200 | 2.010 |
Why?
| | Soft Tissue Infections | 4 | 2018 | 30 | 1.970 |
Why?
| | Bacteremia | 7 | 2024 | 161 | 1.890 |
Why?
| | Abscess | 4 | 2015 | 75 | 1.480 |
Why?
| | Anti-Infective Agents | 7 | 2020 | 227 | 1.430 |
Why?
| | Ambulatory Care | 6 | 2020 | 482 | 1.410 |
Why?
| | Skin Diseases | 3 | 2015 | 125 | 1.270 |
Why?
| | Hospitalization | 7 | 2017 | 1785 | 1.250 |
Why?
| | Drug Prescriptions | 3 | 2020 | 248 | 1.230 |
Why?
| | Otitis | 2 | 2024 | 9 | 1.210 |
Why?
| | Staphylococcal Infections | 5 | 2023 | 346 | 1.180 |
Why?
| | Conjunctivitis | 2 | 2023 | 19 | 1.050 |
Why?
| | Guideline Adherence | 4 | 2022 | 523 | 0.900 |
Why?
| | Cellulitis | 2 | 2014 | 47 | 0.880 |
Why?
| | Fluoroquinolones | 3 | 2024 | 42 | 0.810 |
Why?
| | Urinary Tract Infections | 3 | 2018 | 136 | 0.810 |
Why?
| | Inpatients | 3 | 2020 | 388 | 0.790 |
Why?
| | Gram-Negative Bacterial Infections | 2 | 2018 | 39 | 0.750 |
Why?
| | Cross Infection | 2 | 2015 | 205 | 0.730 |
Why?
| | Retrospective Studies | 20 | 2024 | 12978 | 0.700 |
Why?
| | Drug Resistance, Bacterial | 3 | 2017 | 155 | 0.670 |
Why?
| | Substance Abuse, Intravenous | 2 | 2020 | 80 | 0.670 |
Why?
| | Pharyngitis | 1 | 2018 | 25 | 0.650 |
Why?
| | Smartphone | 1 | 2018 | 67 | 0.630 |
Why?
| | Infection Control | 2 | 2017 | 135 | 0.600 |
Why?
| | Humans | 49 | 2024 | 118974 | 0.600 |
Why?
| | Nitrofurantoin | 1 | 2017 | 7 | 0.600 |
Why?
| | Colorado | 9 | 2020 | 4196 | 0.600 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2017 | 14 | 0.590 |
Why?
| | Cystitis | 1 | 2017 | 21 | 0.590 |
Why?
| | Emergency Service, Hospital | 5 | 2020 | 1865 | 0.560 |
Why?
| | Staphylococcus aureus | 3 | 2023 | 394 | 0.550 |
Why?
| | Mobile Applications | 1 | 2018 | 147 | 0.550 |
Why?
| | Sinusitis | 1 | 2018 | 175 | 0.550 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 24 | 0.520 |
Why?
| | Drug Users | 1 | 2015 | 39 | 0.520 |
Why?
| | Acute Disease | 4 | 2023 | 940 | 0.510 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 37 | 0.490 |
Why?
| | Medication Therapy Management | 1 | 2015 | 72 | 0.480 |
Why?
| | Child | 12 | 2024 | 19129 | 0.470 |
Why?
| | Cohort Studies | 9 | 2024 | 5116 | 0.460 |
Why?
| | Osteomyelitis | 2 | 2012 | 110 | 0.450 |
Why?
| | Practice Guidelines as Topic | 4 | 2017 | 1440 | 0.450 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2023 | 190 | 0.440 |
Why?
| | Streptococcus pneumoniae | 2 | 2023 | 141 | 0.440 |
Why?
| | Community-Acquired Infections | 5 | 2017 | 143 | 0.440 |
Why?
| | Escherichia coli | 1 | 2017 | 758 | 0.440 |
Why?
| | Patient Discharge | 2 | 2017 | 796 | 0.430 |
Why?
| | Critical Pathways | 1 | 2013 | 79 | 0.420 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2012 | 40 | 0.420 |
Why?
| | Histoplasmosis | 1 | 2011 | 15 | 0.410 |
Why?
| | Drug Utilization Review | 3 | 2016 | 60 | 0.400 |
Why?
| | Humeral Head | 1 | 2011 | 14 | 0.400 |
Why?
| | Fistula | 1 | 2011 | 27 | 0.390 |
Why?
| | Middle Aged | 15 | 2018 | 27617 | 0.380 |
Why?
| | Muscular Diseases | 1 | 2011 | 107 | 0.380 |
Why?
| | Adult | 18 | 2024 | 31512 | 0.380 |
Why?
| | Arm | 1 | 2011 | 106 | 0.380 |
Why?
| | Ambulatory Care Facilities | 2 | 2024 | 218 | 0.370 |
Why?
| | Outpatients | 3 | 2021 | 325 | 0.340 |
Why?
| | Female | 20 | 2021 | 61565 | 0.340 |
Why?
| | Respiratory Tract Infections | 1 | 2013 | 331 | 0.340 |
Why?
| | Male | 18 | 2024 | 57801 | 0.330 |
Why?
| | Sepsis | 2 | 2024 | 531 | 0.310 |
Why?
| | Hospitals | 3 | 2024 | 598 | 0.300 |
Why?
| | Academic Medical Centers | 3 | 2017 | 422 | 0.290 |
Why?
| | Prescriptions | 2 | 2018 | 63 | 0.280 |
Why?
| | Drug and Narcotic Control | 2 | 2016 | 28 | 0.280 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 942 | 0.280 |
Why?
| | Aged, 80 and over | 5 | 2018 | 6561 | 0.270 |
Why?
| | Health Services Research | 1 | 2008 | 385 | 0.260 |
Why?
| | HIV | 1 | 2006 | 210 | 0.250 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 233 | 0.250 |
Why?
| | Daptomycin | 1 | 2023 | 19 | 0.240 |
Why?
| | Child, Preschool | 4 | 2021 | 9491 | 0.230 |
Why?
| | Aged | 7 | 2024 | 19657 | 0.230 |
Why?
| | Pandemics | 2 | 2022 | 1355 | 0.230 |
Why?
| | Program Evaluation | 3 | 2017 | 845 | 0.230 |
Why?
| | Organizational Policy | 2 | 2017 | 70 | 0.220 |
Why?
| | Cephalosporins | 2 | 2023 | 27 | 0.210 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.200 |
Why?
| | Muscle, Skeletal | 1 | 2011 | 1515 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1244 | 0.200 |
Why?
| | Prospective Studies | 3 | 2022 | 6471 | 0.200 |
Why?
| | Treatment Outcome | 6 | 2023 | 9342 | 0.200 |
Why?
| | Logistic Models | 2 | 2018 | 1901 | 0.200 |
Why?
| | Risk Factors | 5 | 2014 | 9000 | 0.200 |
Why?
| | Bacterial Infections | 2 | 2020 | 227 | 0.190 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 736 | 0.190 |
Why?
| | Electronic Health Records | 2 | 2024 | 829 | 0.180 |
Why?
| | Private Sector | 1 | 2020 | 51 | 0.180 |
Why?
| | Health Services Accessibility | 1 | 2006 | 781 | 0.180 |
Why?
| | Drug Combinations | 2 | 2024 | 291 | 0.170 |
Why?
| | Mass Screening | 1 | 2006 | 1052 | 0.170 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 60 | 0.160 |
Why?
| | Hospitals, Teaching | 1 | 2018 | 104 | 0.160 |
Why?
| | Insurance, Health | 1 | 2020 | 244 | 0.160 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 4552 | 0.150 |
Why?
| | Pneumonia, Bacterial | 2 | 2017 | 110 | 0.150 |
Why?
| | Drug Costs | 1 | 2017 | 94 | 0.150 |
Why?
| | Medical Audit | 1 | 2017 | 75 | 0.150 |
Why?
| | Medical Records | 1 | 2017 | 163 | 0.140 |
Why?
| | Linear Models | 1 | 2018 | 827 | 0.130 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 178 | 0.130 |
Why?
| | Time | 1 | 2015 | 77 | 0.130 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 67 | 0.130 |
Why?
| | Treatment Failure | 1 | 2016 | 341 | 0.130 |
Why?
| | Debridement | 2 | 2012 | 79 | 0.120 |
Why?
| | Pharmacists | 1 | 2017 | 238 | 0.120 |
Why?
| | Wound Infection | 1 | 2014 | 31 | 0.120 |
Why?
| | Hypokalemia | 1 | 2014 | 31 | 0.120 |
Why?
| | Safety Management | 1 | 2015 | 109 | 0.120 |
Why?
| | Infant | 3 | 2023 | 8293 | 0.120 |
Why?
| | Quality Improvement | 1 | 2021 | 963 | 0.120 |
Why?
| | Urinalysis | 1 | 2013 | 68 | 0.110 |
Why?
| | Adolescent | 3 | 2018 | 18480 | 0.110 |
Why?
| | Catheter-Related Infections | 1 | 2013 | 60 | 0.110 |
Why?
| | Age Factors | 1 | 2020 | 2995 | 0.110 |
Why?
| | Diabetic Foot | 1 | 2012 | 23 | 0.110 |
Why?
| | Limb Salvage | 1 | 2012 | 52 | 0.110 |
Why?
| | Databases, Factual | 1 | 2017 | 1231 | 0.100 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2012 | 79 | 0.100 |
Why?
| | Hospitals, Urban | 1 | 2012 | 129 | 0.100 |
Why?
| | HIV Infections | 1 | 2006 | 2459 | 0.100 |
Why?
| | Histoplasma | 1 | 2011 | 13 | 0.100 |
Why?
| | Streptomycin | 1 | 2011 | 14 | 0.100 |
Why?
| | Penicillin G | 1 | 2011 | 7 | 0.100 |
Why?
| | Enterococcus faecalis | 1 | 2011 | 24 | 0.100 |
Why?
| | Algorithms | 1 | 2018 | 1541 | 0.100 |
Why?
| | Bacteria | 2 | 2023 | 757 | 0.100 |
Why?
| | Young Adult | 2 | 2018 | 10793 | 0.090 |
Why?
| | Blood | 1 | 2010 | 100 | 0.090 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2011 | 67 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2013 | 364 | 0.090 |
Why?
| | United States | 3 | 2021 | 12555 | 0.080 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 69 | 0.080 |
Why?
| | Critical Care | 1 | 2013 | 492 | 0.080 |
Why?
| | Incidence | 1 | 2015 | 2424 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4708 | 0.080 |
Why?
| | Endocarditis | 1 | 2008 | 33 | 0.080 |
Why?
| | Recurrence | 1 | 2010 | 975 | 0.080 |
Why?
| | DNA, Bacterial | 1 | 2009 | 314 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2011 | 378 | 0.070 |
Why?
| | Ultrasonography | 1 | 2011 | 716 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1384 | 0.070 |
Why?
| | Infectious Disease Medicine | 2 | 2016 | 10 | 0.070 |
Why?
| | Epidemiology | 2 | 2016 | 15 | 0.070 |
Why?
| | Echocardiography | 1 | 2008 | 556 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 2013 | 772 | 0.070 |
Why?
| | Radiography | 1 | 2008 | 861 | 0.070 |
Why?
| | Ceftazidime | 1 | 2024 | 5 | 0.060 |
Why?
| | Carbapenems | 1 | 2024 | 16 | 0.060 |
Why?
| | Aztreonam | 1 | 2023 | 8 | 0.060 |
Why?
| | Interrupted Time Series Analysis | 1 | 2023 | 45 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 50 | 0.060 |
Why?
| | Nasopharynx | 1 | 2023 | 64 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2008 | 648 | 0.060 |
Why?
| | Administration, Intravenous | 1 | 2023 | 136 | 0.060 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 48 | 0.060 |
Why?
| | Microbial Sensitivity Tests | 1 | 2024 | 302 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2022 | 81 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 387 | 0.050 |
Why?
| | Health Facilities | 1 | 2020 | 75 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3174 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1687 | 0.040 |
Why?
| | Coagulase | 1 | 2018 | 6 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 70 | 0.040 |
Why?
| | Staphylococcus | 1 | 2018 | 68 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2018 | 269 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2018 | 324 | 0.040 |
Why?
| | Clinical Studies as Topic | 1 | 2017 | 6 | 0.040 |
Why?
| | Cost Savings | 1 | 2017 | 77 | 0.040 |
Why?
| | Pharmacy Service, Hospital | 1 | 2017 | 86 | 0.040 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 66 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2874 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 158 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2020 | 497 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 505 | 0.030 |
Why?
| | Leadership | 1 | 2017 | 311 | 0.030 |
Why?
| | Fever | 1 | 2013 | 283 | 0.030 |
Why?
| | Drug Synergism | 1 | 2011 | 339 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 380 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 1166 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1795 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2012 | 4596 | 0.010 |
Why?
|
|
Jenkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|